Skip to main content
REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.84
-0.13 (-1.45%)
At close: May 30, 2025, 4:00 PM
8.90
+0.06 (0.68%)
After-hours: May 30, 2025, 7:48 PM EDT

REGENXBIO Revenue

REGENXBIO had revenue of $89.01M in the quarter ending March 31, 2025, with 469.79% growth. This brings the company's revenue in the last twelve months to $156.72M, up 80.70% year-over-year. In the year 2024, REGENXBIO had annual revenue of $83.33M, down -7.66%.

Revenue (ttm)
$156.72M
Revenue Growth
+80.70%
P/S Ratio
2.91
Revenue / Employee
$443,960
Employees
353
Market Cap
443.42M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202483.33M-6.91M-7.66%
Dec 31, 202390.24M-22.48M-19.94%
Dec 31, 2022112.72M-357.62M-76.03%
Dec 31, 2021470.35M315.78M204.30%
Dec 31, 2020154.57M119.33M338.70%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 63.92B
AbbVie 57.37B
AstraZeneca 54.98B
Novartis AG 53.22B
Eli Lilly and Company 49.00B
Novo Nordisk 43.92B
Revenue Rankings

RGNX News

More News